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Rapid Alteration in Circulating Free Thyroxine Modulates
Pituitary Type 11 5' Deiodinase and Basal Thyrotropin Secretion in the Rat
Susan L. Abend, Shih Lieh Fang, Sharon Alex, Lewis E. Braverman, and Jack L. Leonard
Departments ofMedicine, Nuclear Medicine and Physiology, University ofMassachusetts Medical School,
Worcester, Massachusetts 01655
Abstract
TSH secretion is decreased by both T4 and T3. This negative
feedback control ofTSH secretion has been correlated with an
increase in pituitary nuclear T3 content, and it is not clear
whether T4 exerts its effect directly on the thyrotroph or after
its deiodination to T3. However, levels of the pituitary enzyme
catalyzing T4 to T3 conversion, 51)-II, are decreased in the pres-
ence of an increased amount of T4. Thus, it is unclear why the
thyrotroph would have a mechanism for modulating the produc-
tion of T3, if T3 is, in fact, the sole bioactive signal providing
negative feedback inhibition.
To examine this apparent paradox, we administered EMD
21388, a compound which inhibits the binding of T4 to transth-
yretin resulting in a rapid increase in circulating free T4 levels,
to rats pretreated with radiolabeled T4 and T3. We observed
increases in pituitary and liver T4 content of >150%, without
increases in the respective tissue T3 contents. The EMD
21388-treated rats also exhibited a 25% decrease in pituitary
51)-II activity (103.8±15.8 fmol 125I released * mg pro-
tein-' h-1, vs. control, 137.4±15.9, mean±SE), as did rats
treated with sodium salicylate, another compound that inhibits
T4-TTR binding (100.8±7.1). TSH levels significantly de-
creased 2 h after the administration ofEMD 21388. These data
demonstrate that despite a T4-mediated decrease in pituitary
5D-II activity, an increase in 14 independently decreases TSH
secretion. (J. Clin. Invest. 1991. 88:898-903.) Key words: thy-
rotropin * flavonoid * deiodinase * transthyretin * thyroxine
Introduction
Thyrotropin (TSH)1 regulates the synthesis and secretion of
thyroxine (T4) and triiodothyronine (T3) from the thyroid
gland. Pituitary TSH secretion is stimulated by thyrotropin
releasing hormone (TRH), and decreased by other hypotha-
lamic factors, including dopamine and somatostatin (1). Thy-
roid hormones play a major role in regulating TSH secretion.
Portions of this work were presented to the 72nd Annual Meeting of
the Endocrine Society, 20-24 June 1990, and the 10th International
Thyroid Congress, 3-8 February 1991.
Receivedfor publication 21 November 1990 and in revisedform 30
April 1991.
1. Abbreviations used in this paper: 5'D-II, type II 5' deiodinase; T3,
triiodothyronine; T4, thyroxine; TRH, thyrotropin-releasing hormone;
TSH, thyrotropin; TTR, transthyretin.
In thyroidectomized rats, the administration of physiologic re-
placement doses of L-T3 decreases serum TSH by - 50% in 2
h, and a similar decrease is seen after the administration of
L-T4 (2, 3). Silva and Larsen reported that, following the intra-
venous administration of 70 ng L-T3/l00 g body weight or a
10-fold higher amount of T4, the fall in serum TSH was asso-
ciated with a rise in the percentage of T) bound to pituitary
nuclear receptors (3). This led to the suggestion that T4 exerts
its inhibitory effect on TSH secretion primarily after its deio-
dination to T3.
This idea was further supported by a number ofsubsequent
findings. First, pituitary TSH suppression was dependent upon
nuclear T3 content and serum T3 concentration (4). Second,
the simultaneous administration of replacement doses of L-T3
and L-T4 doubled the pituitary nuclear T3 content and aug-
mented the decrease in serum TSH beyond that ofL-T3 admin-
istration alone (4). Furthermore, the administration of iopan-
oic acid, a potent inhibitor of T4 to T3 conversion, prevented
the T4 induced decrease in TSH secretion in thyroidectomized
rats (5, 6). lopanoic acid was also found to block the effect ofT4
on TRH-induced TSH secretion in euthyroid rats (7). In intact
rats, Emerson et al. reported that serum T3 appears to more
closely correlate with serum TSH levels than serum T4 (8). It
became clear, then, that both circulating T3 and the intrapitui-
tary conversion of T4 to T3 play key roles in the regulation of
TSH secretion. The physiological importance of pituitary io-
dothyronine 5'-deiodination was underscored by the finding
that 50% of pituitary T3 is generated locally from T4 in euthy-
roid rats (9).
If T3 is the major signal inhibiting TSH secretion, then
under conditions in which serum T4 is increased and serum T3
remains unchanged, any decrease in TSH levels should be de-
pendent upon local pituitary T3 production via type II 5' deio-
dinase (5D-II), the pituitary enzyme catalyzing T4 to T3 con-
version (10). Interestingly, however, numerous studies have
provided in vivo and in vitro evidence that an increase in the T4
concentration rapidly decreases 5D-II activity (11-16). This
would appear paradoxical in a system thought to respond in a
negative-feedback fashion, since the intracellular concentra-
tion of T3, the bioactive signal, would be expected to remain
constant over a wide range of T4 concentrations.
To examine this paradox, we pretreated rats with [12SI]-T4
and [131I]-T3 and studied the intrapituitary thyroid hormone
content and 5D-II activity after administration ofEMD 21388
(3-methyl-4',6-dihydroxy-3',5'-dibromo-flavone). This syn-
thetic flavonoid blocks the binding of T4 to transthyretin
(TTR), the major thyroid hormone binding protein in the rat.
Intraperitoneal administration of EMD 21388 increases the
serum free T4 concentration and decreases the serum total T4
within 3 min, without affecting serum free T3 levels (17). Basal
serum TSH levels decrease within 1-2 h after EMD 21388
administration, and remain depressed for at least 4 h (17, 18).
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This model allowed us to examine the negative-feedback con-
trol ofbasal TSH secretion under steady-state conditions, with-
out requiring the administration ofpharmacologic amounts of
thyroid hormones.
We observed a > 150% increase in the pituitary T4 content
in the EMD 21 388-treated animals, without an increase in pitu-
itary T3 content derived from either local deiodination or from
the circulation. Pituitary 5D-IT activity was decreased. These
findings were associated with a decrease in serum TSH concen-
tration. Thus it appears likely that T4 can act independently to
suppress basal TSH secretion in euthyroid rats, and may, there-
fore, be an additional bioactive signal to the thyrotroph.
Methods
Animals and reagents. Male Sprague-Dawley rats, 200-250 g, were
obtained from Charles River Laboratories (Kingston, RI). They were
maintained under standard conditions with a 12-h light cycle, and were
allowed ad libitum access to Purina Standard Chow (Ralston-Purina,
St. Louis, MO) and water before all studies.
EMD 21388 was kindly supplied by E. Merck (Darmstat, FRG) and
was dissolved in 40 mM NaOH and given intraperitoneally. Sodium
salicylate was dissolved in H20 and given by gavage. [1251]-T4 and ['3'I]-
T3 were freshly prepared from T3 and T2 (Henning, Berlin, FRG) by
methods previously described (19). 125I was obtained from Amersham
(Arlington Heights, IL), and 1311 from New England Nuclear (Boston,
MA). The purity of each radiolabeled iodothyronine was > 95%, as
determined by HPLC analysis. Both tracers were mixed in normal rat
serum and administered intravenously, or used in the determination of
5D-II activity.
Experimental procedures. Tissue iodothyronine levels were exam-
ined in rats given 250 gCi of ['251J-T4 (2.2 Ci/,mol) 16 h, and 25 .Ci
['31I]-T3 (- 2.5 Ci/Mmol) 1 h before the study, using a modification of
the method of Silva et al. (9). At time 0, group I rats were given i.p.
ketamine anaesthesia and sacrificed by aortic exsanguination. Group II
rats were given 40 mM NaOH vehicle, and group III rats were given
EMD 21388 (2 Amol/100 g i.p.). These two groups were sacrificed 1 h
later. Rats were perfused with 60-90 ml of saline. Pituitaries and 0.5 g
liver were harvested and homogenized in buffer containing 10 mM
Hepes and 10 mM iopanoic acid. Radioactivities in aliquots of serum,
liver, and pituitary homogenates were measured in a gamma well
counter (Autogamma 5000; Packard Instrument Co., Inc., Arlington
Heights, IL). Corrections for decay, energy cross-over, and background
were made for both isotopes. Tissue T4 and T3 content were analyzed
using descending paper chromatography in a solvent system contain-
ing 1:5:6 hexane, t-amyl alcohol, and 2NNH40H (20). Bands ofT4 and
T3 were identified by staining with deazotized sulfanilic acid (Pauly's
reagent) and iodine was identified with palladium chloride stain. Each
T3 and T4 band was cut, counted, and the percentage of total counts
was determined by dividing the counts for each isotope in both the T3
and T4 bands by the total counts present on each paper strip. The
percentage oftotal counts was then multiplied by the counts present in
a milligram of tissue, and expressed as a percent of the total counts of
each isotope administered.
In the second set of experiments, group I rats were treated with 40
mM NaOH vehicle i.p. Group II rats received EMD 21388 (2 Mmol/
100 g i.p.), and group III animals received sodium salicylate (30 mg/
100 g p.o.). All rats were sacrificed 1 h later by decapitation and trunk
blood and pituitaries were collected. Serum was assayed for TSH, total
T4, total T3, and free T4. Pituitaries were immediately placed in liquid
nitrogen, and later homogenized in 800 ,l of a buffer containing 250
mM sucrose, 20 mM Hepes, 1 mM EDTA, and 1 mM DTT, pH 7.0,
just before measuring 51)II activity.
In the third experiment, rats were treated with either 40mM NaOH
vehicle or EMD 21388 (2 ,gmol/100 g i.p.) and sacrificed 1 or 2 h later.
Trunk blood was collected, and serum was assayed for TSH.
Assays. Serum T4 and T3 were measured by RIA as previously de-
scribed (21). Serum TSH concentrations were measured by RIA using
materials kindly supplied by the National Institutes ofDiabetes, Diges-
tive and Kidney Diseases National Hormone and Pituitary Program,
National Institutes of Health, Bethesda, MD. All three hormones were
measured in duplicate, in random order, and in the same assay for each
experiment. The intraassay coefficients of variation were: T4, < 1%;
T3, <5%;andTSH, <1%.
Salicylate levels were determined by a modification of Trinder's
method (22) in the serum of salicylate-treated rats, and in equilibrium
dialysis buffer after an 18-h incubation with serum containing 2.1 mM
sodium salicylate. Percent free T4was measured in duplicate by equilib-
rium dialysis of undiluted serum at 370C for 18 h as described previ-
ously (21), and the free T4 concentration was calculated as the product
of total T4 and percent free T4.
To assess whether a significant concentration of"free" EMD 21388
could be present in vivo and available to cells, we used the ability of
EMD 21388 to displace T4 from serum as an index of"free" flavonoid.
In the first experiment, increasing quantities of EMD 21388 were
added to serum aliquots, creating concentrations of 0-5 mM. In the
second experiment, rats were treated with either 2 gmol/100 g or 4
Mmol/100 g EMD 21388 intravenously, sacrificed in 3 min, and trunk
blood was obtained. Each serum sample was dialyzed against an equal
volume of phosphate buffer for 18 h at 37°. After dialysis, the dialysate
was added to an equal volume of fresh normal rat serum, and this
mixture was incubated with tracer [1251]-T4 for 30 min. 50 y1 aliquots of
each incubation mixture were loaded onto nondenaturing PAGE gels
and run for 5 h at 140 V in recirculating 0.02 M phosphate buffer (23).
PAGE-gels were dried and exposed for radioautography for 24 h, and
the quantity of radiolabeled T4 bound to TTR was determined by
counting the labeled TTR spot and expressing it as a percentage ofthe
total counts in that aliquot.
5D-II activity was measured by the release of 1251 from [1251]-T4 in
the presence of 1 mM propylthiouracil, as previously described (12),
using 20-sul aliquots of pituitary homogenate and 100 or 200 pM [1251]_
T4 as substrate. Protein determinations were performed using the Bio-
Rad Protein Assay (Bio-Rad Laboratories, Inc., Richmond, CA).
Statistical analysis. All data are presented as the mean±SE. Data
were analyzed using one way analysis of variance (ANOVA) and Stu-
dent-Neumann-Keuls multiple comparisons test (SNK), or analysis of
covariance, where appropriate.
Results
Effect ofEMD 21388 on the kinetics ofradioiodine-labeled T3
and T4. The ratio of pituitary to serum 1251 counts in the con-
trol group at time zero (0.23+0.02) was not different from that
in the NaOH-treated group at 60 min (0.20±0.02), indicating
that the rats were in equilibrium at the time ofthe experiment.
The 1251 pituitary to serum ratio in the EMD 21388-treated
group, however, was approximately double that of either con-
trol group (0.47±0.06, P < 0.05). Table I illustrates the pitu-
itary content of [1251]-T4, ['251]-T3, and [131I]-T3. These results
indicate that the differences in pituitary 1251 counts can be di-
rectly attributed to an increase in the pituitary T4 content
alone, and that this increase is not accompanied by a corre-
sponding change in [125I]-T3 levels. There was also no increase
in the systemic contribution to pituitary T3 content, as demon-
strated by the pituitary ['311]-T3 levels (Table I).
The content of hepatic radioiodine-labeled iodothyronines
displayed a similar pattern (Table I). Again, the liver to serum
ratio of 1251I was markedly higher in the EMD 21388 treatment
group than in either of the control groups. (1.59 + 0.11 in the
EMD 21388-treated rats, vs. 0.50 + 0.04 in the group I control
rats, and 0.58 + 0.03 in the group II control rats; P < 0.05 by
ANOVA). The liver content of [1251]-T4 was elevated in the
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Table I. Pituitary and Liver Fractionated Radioiodothyronine Content in EMD 21388-treated Rats and Controls
Pituitary Liver
Group I II III I II III
Control Control Control Control
(O h) (I h) EMD (O h) (I h) EMD
% dose/mg
tissue
[1251]-T4 x 10-' 3.27±0.46 3.64±0.49 5.70±0.52* 10.79±0.98 9.11±1.20 14.36±1.33*
['25j]-T3 x 10-7 2.25±0.33 2.51±0.16 2.97±0.49 1.65±0.21 1.98±0.10 1.78±0.20
[131I]-T3 x 10-' 1.80±0.24 1.74±0.13 1.63±0.14 0.76±0.05 0.95±0.12 0.60±0.04
Rats were treated with 250 GCi of ['25I]-T4 16 h before the study, and 25 MCi ['1I]-T3 1 h before the study. One control group was sacrificed at
time 0, and one control group was given 40 mM NaOH vehicle and sacrificed at 1 h. EMD 21388-treated rats received 2 umol/100 g and were
sacrificed at 1 h. The data include the results of two separate experiments, each with three to five rats per group, and are expressed as the
mean±SE. * P < 0.05 by ANOVA.
flavonoid-treated rats compared to rats in groups I and II,
whereas the level of [125I]-T3 was not different. The liver con-
tent of [131I]-T3 (circulating T3) was slightly lower in the EMD
21388-treated rats.
Effect ofEMD 21388 and salicylate administration on pitu-
itary S'D-II activity. To determine why an increase in the pitu-
itary content of T4 was not associated with a corresponding
increase in pituitary T3 content, we studied the 5D-II activity
in pituitary homogenates ofanimals treated with either vehicle,
EMD 21388, or sodium salicylate, another compound
previously shown to partially inhibit T4 binding to TTR in the
rat (24).
To ensure an optimal estimation ofpituitary 5D-II activity,
we measured the rate of 5D-II activity under reaction condi-
tions that showed linear production ofT3 at T4 concentrations
approximately two- and fourfold greater than those estimated
to be present in the pituitary. T3 production was linear for up to
40 min (data not shown) and the 5D-II activity carried out at
100 and 200 pM ['25I]-T4 is shown in Fig. 1. EMD 21388 and
salicylate administration significantly decreased pituitary 5D-
II activity at both substrate concentrations, and greater enzyme
activity was present in all groups using 200 pM T4. This sug-
gests that the similar levels of pituitary T3 content seen in all
groups in the first set of experiments were due to decreased
enzyme activity, and not to a saturation of enzyme capacity.
Determination offreeEMD 21388 activity in serum. When
EMD 21388 was added to serum in increasing concentrations
and then subject to equilibrium dialysis in duplicate, the per-
centage of [125I]-T4 bound to TTR in normal serum mixed with
dialysate is shown in Fig. 2. In rats given 2 or 4 gmol EMD
21388/100 g body wt intravenously, sacrificed 3 min later,
there was no evidence of "free" EMD 21388 activity.
(57.5±1.6% in rats treated with 4 Amol EMD 21388/100 g
body wt; 58.0±1.1% at 2 ,umol/100 g, vs. 55.7±1.5% in con-
trols; 4 rats per group, P = NS).
Effect of salicylate added in vitro on pituitary S'D-II. To
determine whether sodium salicylate was a direct inhibitor of
5D-Il, we assayed aliquots ofnormal pituitary homogenate for
5D-II activity in the presence of 0, 2, and 10 mM sodium
salicylate. The activities in triplicate samples were 47.0, 65.6,
and 57.1 fmol 125I released-mg protein-' h-, respectively
(NS). Because the serum salicylate concentration in animals
treated with 30 mg salicylate/100 g body wt was 34.2 mg/
dl± 1.0 (2.1 mM), it is clear that this administered dose ofsalicy-
late does not directly inhibit enzyme activity.
Effects ofEMD 21388 and salicylate on serum TSH, total
T74, free T4, and total T3 concentrations. Table II illustrates the
serum TSH and thyroid hormone levels in the three groups.
The decrease in TSH at 1 h in the EMD 21388-treated group,
although not statistically significant, was similar to that
previously reported (18). The serum TSH concentration was
also slightly lower in the salicylate-treated group. In both treat-
ment groups there was a significant decrease in the serum total
T4 concentration compared to the control group. There was a
significant increase in the percent free T4 in the EMD 21388-
200
100
* 100pM
* 200 pM
Figure 1. The effects of EMD 21388 and sodium salicylate adminis-
tration on pituitary 5D-II activity using 100 pM and 200 pM [125I1-T4
as substrates. Rats were treated with either 40 mM NaOH vehicle,
2 ,umol EMD 21388/100 g body wt, or 30 mg sodium salicylate/100
g body wt and sacrificed 1 h later. Pituitaries were homogenized, and
aliquots used to determine the fmol 125I released . mg protein-' - h-' at
each substrate concentration, after 10, 20, and 40 min of incubation.
Activities were calculated by least squares regression analysis for each
animal, and the means in each treatment group are shown above.
Data are reported as the mean±SE of three separate experiments, with
four to eight rats per group per experiment. Error bars indicate stan-
dard error. *P < 0.05 vs. control (analysis of covariance). **P < 0.05
vs. control (analysis of covariance).
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Figure 2. Estimation of serum free
EMD 21388 activity. 0-1,000 ,M
EMD 21388 was added to normal
rat serum in duplicate, and 1 ml of
each was subject to equilibrium di-
alysis overnight. Each dialysate was
added to normal rat serum contain-
ing [1251]-T4, and the mixture was
subject to SDS-PAGE. The radiola-
beled band corresponding to TTR
1 00 0 was counted and expressed as a per-
centage of total radioactivity for that
lane.
treated group due to the inhibition ofT4 binding by TTR, and
thus, a less pronounced but still highly significant increase in
the serum free T4 concentration. Salicylate administration has
been reported to increase the percent free T4 measured by equi-
librium dialysis (24), and the percent free T4 was significantly
higher using this technique (salicylate-treated, 0.051±0.003%,
vs. control, 0.032±0.002%, P < 0.05). However, we established
in a separate experiment, that - 70% ofthe serum salicylate is
present in the dialysate at equilibrium, and, therefore, equilib-
rium dialysis cannot accurately reflect the percent free T4 pres-
ent in vivo. Thus, the free T4 concentration cannot be calcu-
lated. It is likely, however, that the serum free T4 concentration
in these rats is increased because Larsen has reported that salicy-
late, when added to human serum at a concentration of 30
mg/dl, doubles the free T4 concentration as measured by an
ultrafiltration technique (25).
Serum TSH concentrations I and 2 h after administration
ofEMD 21388. To demonstrate that the decrease in serum
TSH becomes more pronounced over time after EMD 21388
administration, rats were treated with EMD 21388 and serum
Table II. Effects ofEMD 21388 and Sodium Salicylate on Serum
TSH, T4, Percent Free T4, and T3 1 h after Administration
Control EMD 21388 Salicylate
TSH (juU/ml) 63.7±6.8 55.8±4.6 49.4±3.3
T4 (ug/dl) 5.68±0.02 3.00±0.16* 2.93±0.22*
% Free T4 0.028±0.001 0.115±0.005*
Free T4 (ng/dl) 1.57±0.09 3.42±0.23*
T3 (ng/dl) 81.37±4.31 65.75±4.18* 55.38±3.67*
Serum values were measured from trunk blood obtained 1 h after
treatment with either 40 mM NaOH vehicle, 2 Mmol EMD 21388/100
g body wt, or 30 mg sodium salicylate/100 g body wt. Data are re-
ported as the mean±SE of three separate experiments, with four to
eight rats per group per experiment. * P < 0.05 vs. controls by
ANOVA and SNK.
TSH concentrations measured 1 and 2 h later. The results are
shown in Fig. 3 and demonstrate a significantly lower serum
TSH concentration in the rats treated with EMD 21388 com-
pared with control values at 2 h. These results are similar to
those previously reported (18).
Discussion
These data demonstrate that an acute elevation in serum free
T4, due to inhibition of T4 binding to TTR by EMD 21388,
rapidly increases the pituitary and liver content of T4. In the
pituitary, this increased amount ofT4 did not result in a greater
T3 content, because the enzyme catalyzing the conversion ofT4
to T3, 5D-IT, was decreased. The data further indicate that this
decrease in enzyme activity is directly related to the increased
concentration of substrate T4, because salicylate administra-
-I-
0
c
0
MD
P
90
60
30
O0
control
Figure 3. Serum TSH concentrations I and 2 h after EMD 21388
administration. Rats were treated with either 40 mM NaOH vehicle,
or 2 Amol EMD 21388/100 g body wt. There were five rats per group.
Error bars indicate standard error. *P < 0.05 vs. controls by ANOVA
and SNK.
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tion produced a similar decrease in 5)D-II activity in vivo, but
had no effect on 5'D-I1 activity when added in vitro. Although
EMD 21388 added in vitro has been reported to competitively
inhibit 5'D-II, this effect occurs only in concentrations > 1 OM
(26). It is highly unlikely that an administered intraperitoneal
dose of 2 gmol/100 g would provide an intrapituitary concen-
tration of 1 uM. Assuming that the entire injected dose is ab-
sorbed and retained in the circulation, in a 250-g rat the maxi-
mum EMD 21388 serum concentration would be 500 ,M (5
,umol/10 ml serum). We have observed that the apparent "free"
EMD 21388 at this serum concentration causes - 24% dis-
placement of [1251]-T4 from TTR. Assuming that TTR is the
only serum protein that binds EMD 21388, and assuming a 1: 1
stoichiometry, the concentration of free EMD 21388 would be
0.24 [TTR], or 0.24 [5.5,MM] (27), or 1.3,uM. The total amount
of free EMD 21388 in the 10 ml of rat serum would therefore
be 13 nmol. If that free EMD 21388 is equally distributed
throughout the body, the pituitary concentration would be 13
nmol/250 ml, or 52 nM. The effect of EMD 21388 on the
activity of 51D-II in this system is, therefore, likely to be indi-
rect, and caused by its ability to increase the pituitary content
of T4. While in earlier work (18) this effect on pituitary 5D-II
activity was not observed, subsequent in vivo experiments have
demonstrated that the potency of EMD 21388 to inhibit T4
binding to TTR is increased (17) perhaps due to the use of a
more alkaline vehicle in the more recent experiments (17). This
might result in a greater amount of free T4 available to the
pituitary to decrease 51D-II activity.
The ability of T4 to regulate intrapituitary T3 production
has been verified by numerous investigators. Incubation ofpitu-
itary fragments (11) or GH4C1 cells (12) with increasing con-
centrations of T4 resulted in a decrease in deiodination of T4
and T3 production. Others have shown that rats treated with T4
exhibit decreased pituitary deiodinase activity (13-15). Leon-
ard et al. have reported that this effect is not inhibited by cyclo-
heximide and is, therefore, not dependent on protein synthesis
(16). Finally, Lum and co-workers have suggested that 5'-deio-
dinase activity is autoregulated in man, being reduced when
serum T4 concentration is elevated, and increased in the pres-
ence of a lower T4 value (28). The present study demonstrates
that in euthyroid rats, the basal activity of 5'D-II can be de-
creased by - 25% in 1 h by an increase in pituitary T4 content
without the administration of pharmacologic doses of L-T4.
We have also demonstrated that, in the absence of an in-
crease in intrapituitary T3 levels, TSH begins to decrease at 1 h
and decreases even further 2 h after EMD 21388 administra-
tion. Because previous data indicate thatEMD 21388 has a low
affinity for the T3 nuclear receptor (29), and the intracellular T3
that we measured is in dynamic equilibrium with nuclear T3,
there is no reason to expect a difference in T3 nuclear receptor
occupancy between EMD 21388-treated and control rats.
Therefore, basal TSH secretion may decrease independently of
the T3 nuclear content.
The importance ofT3 in inhibiting TSH release is clear and
has been reported to be more important than T4. Hypothyroid
rats treated with iopanoic acid (which blocks both intrapitui-
tary and systemic T4 to T3 conversion) have a lower pituitary
nuclear T3 content than control rats, and TSH secretion is not
decreased in response to an intravenous bolus of T4 (5). Addi-
tionally, T4 does not inhibit the TRH-induced increase in TSH
secretion after pretreatment with iopanoic acid (7). Further-
more, Emerson et al. have recently reported that serum T3
concentrations are more positively correlated with TSH secre-
tion than serum T4 concentrations under physiological condi-
tions (8). Therefore, it is possible that a critical percentage of
nuclear T3 receptors must be occupied to suppress TSH secre-
tion and maintain a basal secretory rate in the euthyroid rat.
However, we have now demonstrated that elevations in pitu-
itary T4 content may decrease basal TSH secretion without an
associated increase in pituitary T3 content.
It is important to note, however, that thyrotrophs consti-
tute only - 10% of the euthyroid pituitary (30), and we may
not be observing an accurate reflection of 5D-II activity and
iodothyronine content in these cells. Studies of enriched pitu-
itary cell pools have shown that, while under hypothyroid con-
ditions, thyrotrophs have less 5'-D activity than other anterior
pituitary cell types, T3 replacement induces a similar, lower
level ofactivity in all cell pools (31). This may indicate that the
5D-II may be less substrate-regulated in the thyrotroph than in
other cell types, and it is possible that proportionately more
thyrotroph-derived T3 is available to its nucleus when pituitary
T4 content is elevated. Alternatively, the thyrotroph may be
dependent, in a paracrine fashion, on T3 generated by other
pituitary cell types. When T3 availability decreases within the
pituitary, TSH secretion is stimulated. However, when T4 con-
tent increases, T3 production is blunted in other cell types such
as lactotrophs and somatotrophs, and these cells are protected
from increased amounts of T3 generated by unchecked local
conversion. Under these conditions the total pool of T3 avail-
able to the thyrotroph is not different from the euthyroid state,
but an additional signal for suppressing TSH secretion, T4,
remains intact.
In summary, we have demonstrated that an acute elevation
in serum free T4 concentration can increase pituitary (and
liver) T4 content, and can rapidly decrease the activity of pitu-
itary 51)-II. Pituitary T3 content does not change and, despite
this, TSH secretion decreases. These results suggest that T4 may
have an effect on TSH secretion independent of its conversion
to T3, and may explain how TSH secretion can decrease in the
presence of a decrease in 5D-II activity.
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